DNA methylation, catalyzed by DNA methyltransferases (DNMT), is a major epigenetic modification that
modulates gene expression. DNMT inhibition is a current challenge in cancer therapy because of inhibition of tumor
suppressor genes (TSG) by hypermethylation. Since the apparition of the first DNMT inhibitors, many global (inhibitors
targeting all the DNMT) and specific DNMT inhibitors have been developed. Unfortunately, the main problem of these
inhibitors is the global effect induced on DNA methylation leading to hypomethylation of tumor suppressor genes but also
oncogenes (and therefore activation/re-expression of them). In this review, DNMT, their implication in cancer
development and progression and their different inhibitors (including mode of action, benefits and limits) will be
discussed. Thus, a new specific methylation inhibition approach will be described. This approach aims to specifically reactivate
tumor suppressor genes without activation of oncogenes by disruption of selective DNMT-including complexes
leading to a targeted hypomethylation.
Keywords: Cancer, DNA methylation, DNMT, DNMT inhibitor, epigenetic, therapy.
Rights & PermissionsPrintExport